Twist Bioscience Corporation Amortization of Intangible Assets
Twist Bioscience Corporation (TWST) reported Amortization of Intangible Assets of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-03
- Twist Bioscience Corporation amortization of intangible assets for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- Twist Bioscience Corporation amortization of intangible assets for the quarter ending 2026-03-31 was $300.00K, a 0.00% change year-over-year.
- Twist Bioscience Corporation amortization of intangible assets for the quarter ending 2025-12-31 was $300.00K, a 0.00% change year-over-year.
- Twist Bioscience Corporation amortization of intangible assets for the quarter ending 2025-09-30 was $300.00K, a 50.00% increase year-over-year.
- Twist Bioscience Corporation amortization of intangible assets for fiscal 2025 was $1.10M, a 73.17% decline from fiscal 2024.
- Twist Bioscience Corporation amortization of intangible assets for fiscal 2024 was $4.10M, a 22.64% decline from fiscal 2023.
- Twist Bioscience Corporation amortization of intangible assets for fiscal 2023 was $5.30M, a 8.16% increase from fiscal 2022.
- Twist Bioscience Corporation amortization of intangible assets for fiscal 2022 was $4.90M, a 880.00% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-03 | $600.00K derived: sum of 2 quarters · filed 2026-08-03 | $800.00K 10-Q · filed 2026-08-03 | $1.20M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-04 | $500.00K 10-Q · filed 2026-05-04 | $900.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.20M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $300.00K 10-Q/A · filed 2026-02-26 | $600.00K derived: sum of 2 quarters · filed 2026-02-26 | $900.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.20M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $600.00K derived: sum of 2 quarters · filed 2026-08-03 | $900.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.10M 10-K · filed 2025-11-17 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-03 | $600.00K derived: sum of 2 quarters · filed 2026-08-03 | $800.00K 10-Q · filed 2026-08-03 | $1.10M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-04 | $500.00K 10-Q · filed 2026-05-04 | $800.00K derived: sum of 3 quarters · filed 2026-05-04 | $2.10M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $300.00K 10-Q/A · filed 2026-02-26 | $500.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.80M derived: sum of 3 quarters · filed 2026-02-26 | $3.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $1.50M derived: sum of 2 quarters · filed 2025-11-17 | $2.80M derived: sum of 3 quarters · filed 2025-11-17 | $4.10M 10-K · filed 2025-11-17 |
| 2024-06-30 | $1.30M 10-Q · filed 2025-08-04 | $2.60M derived: sum of 2 quarters · filed 2025-08-04 | $3.90M 10-Q · filed 2025-08-04 | $5.30M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | $1.30M 10-Q · filed 2025-05-05 | $2.60M 10-Q · filed 2025-05-05 | $4.00M derived: sum of 3 quarters · filed 2025-11-17 | $5.30M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | $1.30M 10-Q · filed 2025-02-03 | $2.70M derived: sum of 2 quarters · filed 2025-11-17 | $4.00M derived: sum of 3 quarters · filed 2025-11-17 | $5.30M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $2.70M derived: sum of 2 quarters · filed 2025-11-17 | $4.00M derived: sum of 3 quarters · filed 2025-11-17 | $5.30M 10-K · filed 2025-11-17 |
| 2023-06-30 | $1.30M 10-Q · filed 2024-08-02 | $2.60M derived: sum of 2 quarters · filed 2024-08-02 | $3.90M 10-Q · filed 2024-08-02 | $5.30M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-02 | $2.70M 10-Q · filed 2024-05-02 | $4.00M derived: sum of 3 quarters · filed 2024-11-18 | $5.40M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | $1.40M 10-Q · filed 2024-02-02 | $2.70M derived: sum of 2 quarters · filed 2024-11-18 | $4.10M derived: sum of 3 quarters · filed 2024-11-18 | $5.50M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $2.70M derived: sum of 2 quarters · filed 2024-11-18 | $4.10M derived: sum of 3 quarters · filed 2024-11-18 | $4.90M 10-K · filed 2024-11-18 |
| 2022-06-30 | $1.40M 10-Q · filed 2023-08-07 | $2.80M derived: sum of 2 quarters · filed 2023-08-07 | $3.60M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $1.40M 10-Q · filed 2023-05-08 | $2.30M 10-Q · filed 2023-05-08 | ||
| 2021-12-31 | $800.00K 10-Q · filed 2023-02-07 | |||
| 2021-09-30 | $500.00K 10-K · filed 2023-11-21 | |||
| 2020-09-30 | $200.00K 10-K/A · filed 2023-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |